On May 30, 2025, Massive Bio participated in the PCC Drop-In Session at ASCO25, an in-person networking event organized by the Precision Cancer Consortium (PCC). The session brought together leading organizations united by a shared mission to advance precision oncology..
A Shared Mission in Precision Oncology
The PCC Drop-In served as a platform for industry members and partner advocates to showcase their initiatives and discuss ongoing PCC-supported projects. These included advancements in liquid biopsy access, comprehensive genomic profiling (CGP), clinical trial matching, and other approaches designed to make precision medicine more accessible to patients worldwide.
Massive Bio’s Representation
Representing Massive Bio at the event, Co-founder and CEO Selin Kurnaz joined discussions with consortium partners and industry stakeholders to highlight how technology and collaboration can bridge long-standing gaps in oncology research and trial access.
Selin’s participation underscored Massive Bio’s ongoing partnership with the PCC and its dedication to using AI-driven precision matching to connect patients with clinical trials quickly, accurately, and at no cost. Her engagement reflected the company’s broader mission: ensuring that every patient, regardless of location or circumstance, has access to cutting-edge therapies and research opportunities.
Collaboration That Drives Progress
By joining the PCC Drop-In, Massive Bio strengthened its ties within a network committed to turning innovation into real-world impact. Events like this demonstrate the value of collective action, where data, technology, and advocacy converge to accelerate progress in precision oncology.
Participation in the PCC Drop-In Session at ASCO25 underscored Massive Bio’s commitment to collaboration and innovation in precision oncology.
Massive Bio is proud to stand among organizations redefining how patients access clinical trials, and remains committed to advancing initiatives that transform the future of cancer care.
